🔎 Trials Near Me

Hjem › Ikke-småcellet lungekreft › Montana

Kliniske studier for Ikke-småcellet lungekreft i Montana

18 studier for Ikke-småcellet lungekreft søker deltakere på steder i Montana.

Byer i Montana

Offisiell studietekst (engelsk)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 3 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • Billings Clinic ( Site 3255), Billings
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07513376

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • Benefis Sletten Cancer Institute, Great Falls
  • og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07388524

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Saint Vincent Frontier Cancer Center, Billings
  • og 4 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • St. Vincent Frontier Cancer Center, Billings
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
  • Bozeman Health Deaconess Hospital - Bozeman Health Cancer Center, Bozeman
  • Bozeman Health Deaconess Hospital - Bozeman Health Clinical Research, Bozeman
  • og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07144280

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • SCL Health - Montana, Billings
  • SCL Health - Montana, Billings
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06758401

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 6 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT03191149

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  • Logan Health Research, Kalispell
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06899126

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  • St. Vincent Frontier Cancer Center, Billings
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 26. aug. 2026 · NCT07288177

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Intermountain Health - St. Vincent Frontier Cancer Center, Billings
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jun. 2026 · NCT06162221

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 3 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 3 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 3 flere
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Bozeman Health Deaconess Hospital, Bozeman
  • og 3 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • Community Hospital of Anaconda, Anaconda
  • Billings Clinic Cancer Center, Billings
  • Montana Cancer Consortium NCORP, Billings
  • og 5 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Billings
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.